CTNM - CIK 0001855175
The table below shows Contineum Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Operating cash flow | -$16.27M | -$14.41M | -$7.97M | -$5.24M |
| Capital expenditure | $312.00K | $47.00K | $147.00K | $52.00K |
| Investing cash flow | -$39.31M | $14.91M | $8.73M | $9.36M |
| Dividends paid | - | - | - | - |
| Stock buybacks | - | - | - | - |
| Financing cash flow | $129.00K | $24.00K |
Contineum Therapeutics, Inc. reported operating cash flow of -$55.31M for fiscal year 2025. That is down 68.4% from -$32.84M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$18.00K |
| -$617.00K |